The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Fri, 16th Apr 2021 15:17

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Tesco PLC - Welwyn Garden City, England-based grocer - Chair John Allan buys 44,426 shares at GBP2.25, worth GBP100,000 on Wednesday. Non-Executive Director Steve Golsby buys 8,608 shares at GBP2.25, worth GBP19,393, on Thursday.

----------

Dechra Pharmaceuticals PLC - Cheshire-based veterinary products - Tony Griffin, managing director of Dechra Veterinary Products EU, sells 25,000 shares at GBP38.52, worth GBP962,950, on Friday. Dechra says Griffin's sale is to widen his investment portfolio for long-term financial planning purposes. He continues to hold 45,650 shares.

----------

OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - Non-Executive Director Stephen Hammond buys 25,000 shares at 51.8 pence, worth GBP12,950, on Thursday. The purchase is his only holding, having joined the board in February. Hammond is a UK member of Parliament.

----------

4D Pharma PLC - Leeds-based live biotherapeutic products - Chief Executive Officer Duncan Peyton and Chief Scientific Officer Alex Stevenson take part in company's USD25.0 million equity raise in March. Peyton and Stevenson each subscribe for 658,840 shares at GBP1.10, together worth GBP1.4 million. Peyton now has 9.5 million shares, a 5.3% stake, and Stevenson 9.4 million.

----------

Power Metal Resources PLC - metals exploration and development in Africa, US and Canada - Chief Executive Paul Johnson buys 500,000 shares at 2.39p each, GBP11,957 in total, on Thursday. Johnson had bought another 500,000 shares on Thursday that was already reported, for a GBP23,452 total investment. He now has 62.5 million shares, a 5.5% stake.

----------

Parsley Box Group PLC - Edinburgh-based ready-meal deliveries - Non-Executive Chair Chris van der Kuyl and wife Heather buy 26,165 shares at GBP1.86 to GBP2.03, worth about GBP50,000, on April 1 and April 12. Van der Kuyl now holds 2.3 million shares directly and 1.6 million indirectly via 4J Studios Ltd, for a 9.4% total stake. Parsley listed on AIM on March 31 at an initial public offering price of 200p.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Non-Executive Director Mark Ward buys 171,242 shares at 40.7p, worth GBP69,695, on Thursday. Ward now has 2.3 million shares, a 13.5% stake. He also has agreed to subscribe to 1.4 million new shares as part of InnovaDerma's placing announced back in January. Finance Director Andrew Dunderdale buys 24,937 shares at 40.1p, also on Thursday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2020 14:39

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

Read more
6 Jul 2020 12:38

Next part of tumour trial begins for 4D Pharma

(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.

Read more
6 Jul 2020 10:17

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

Read more
2 Jul 2020 12:14

Patient enrolment begins for 4D's Covid therapy candidate

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.

Read more
2 Jul 2020 09:16

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

Read more
26 May 2020 10:06

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

Read more
11 May 2020 10:45

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

Read more
20 Apr 2020 11:08

4D Pharma receives expedited approval for coronavirus study

(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.

Read more
20 Apr 2020 10:30

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

Read more
17 Apr 2020 13:53

4D Pharma upbeat on key findings from Blautix study

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.

Read more
17 Apr 2020 10:14

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

Read more
18 Mar 2020 18:09

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

Read more
18 Feb 2020 18:44

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

Read more
18 Feb 2020 09:26

4D Pharma raising at least ?18m via placing and subscription

(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.

Read more
18 Feb 2020 09:03

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.